Seelos Therapeutics Total Liabilities 2010-2022 | SEEL
Seelos Therapeutics total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Seelos Therapeutics Annual Total Liabilities
(Millions of US $) |
| 2021 |
$26 |
| 2020 |
$15 |
| 2019 |
$11 |
| 2018 |
$5 |
| 2017 |
$2 |
| 2016 |
$12 |
| 2015 |
$18 |
| 2014 |
$13 |
| 2013 |
$12 |
| 2012 |
$17 |
| 2011 |
$12 |
| 2010 |
$7 |
| 2009 |
$18 |
Seelos Therapeutics Quarterly Total Liabilities
(Millions of US $) |
| 2022-03-31 |
$25 |
| 2021-12-31 |
$26 |
| 2021-09-30 |
$8 |
| 2021-06-30 |
$8 |
| 2021-03-31 |
$17 |
| 2020-12-31 |
$15 |
| 2020-09-30 |
$3 |
| 2020-06-30 |
$4 |
| 2020-03-31 |
$7 |
| 2019-12-31 |
$11 |
| 2019-09-30 |
$6 |
| 2019-06-30 |
$5 |
| 2019-03-31 |
$9 |
| 2018-12-31 |
$5 |
| 2018-09-30 |
$1 |
| 2018-06-30 |
$2 |
| 2018-03-31 |
$2 |
| 2017-12-31 |
$2 |
| 2017-09-30 |
$3 |
| 2017-06-30 |
$2 |
| 2017-03-31 |
$5 |
| 2016-12-31 |
$12 |
| 2016-09-30 |
$16 |
| 2016-06-30 |
$16 |
| 2016-03-31 |
$17 |
| 2015-12-31 |
$18 |
| 2015-09-30 |
$18 |
| 2015-06-30 |
$15 |
| 2015-03-31 |
$18 |
| 2014-12-31 |
$13 |
| 2014-09-30 |
$8 |
| 2014-06-30 |
$8 |
| 2014-03-31 |
$16 |
| 2013-12-31 |
$12 |
| 2013-09-30 |
$10 |
| 2013-06-30 |
$14 |
| 2013-03-31 |
$17 |
| 2012-12-31 |
$17 |
| 2012-09-30 |
$17 |
| 2012-06-30 |
$12 |
| 2012-03-31 |
$12 |
| 2011-12-31 |
$12 |
| 2011-09-30 |
$8 |
| 2011-06-30 |
$9 |
| 2011-03-31 |
$7 |
| 2010-12-31 |
$7 |
| 2010-09-30 |
|
| 2010-06-30 |
$7 |
| 2010-03-31 |
$17 |
| 2009-12-31 |
$18 |
| 2009-09-30 |
$5 |
| 2009-06-30 |
$6 |
| 2009-03-31 |
$7 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.065B |
$0.000B |
|
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
|
